Generic Name: darunavir + cobicistat + emtricitabine + tenofovir alafenamide
Abbreviation: DRV/c + FTC + TAF
Other Market Name: N/A
Drug Class: Single-Tablet Regimens
Company: Janssen Therapeutics
Approval Status: Experimental
Generic Version Available: No
Experimental Code: N/A
Symtuza has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
Symtuza is an experimental HIV medication. It is currently in Phase III clinical trials. An application for approval was submitted to the FDA in September 2017.
Symtuza contains an approved protease inhibitor (darunavir), an approved boosting agent (cobicistat) and two approved nucleoside/nucleotide reverse transcriptase inhibitors (emtricitabine + tenofovir alafenamide).
Adult Dose: Each tablet contains 800 mg darunavir, 150mg cobicistat, 200mg emtricitabine and 10mg tenofovir alafenamide.
Pediatric Dose: N/A
Dosing Info: If approved, Symtuza will be a complete one-pill, once-daily drug regimen.
Last Revised: October 2, 2017